Published in Healthcare Mergers, Acquisitions and Ventures Week, March 24th, 2007
Revenues amounted to $32,106, as compared to $48,062 for the same quarter last year. Revenues are exclusively derived from the sale of fibrin sealant application devices, HemaSyst(TM)and HemaMyst(TM). Operating expenses amounted to $828,482, as compared to $880,363 for the same quarter last year. The decrease is mainly attributed to a decrease in general and administrative expenses. The consolidated net loss for the quarter amounted to $813,253, or $0.01 per share, as compared to $851,895, or $0.02 per share, for the same quarter last...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week